A case report of severe veno-occlusive disease following autologous stem cell transplantation successfully treated with Defibrotide

被引:1
|
作者
Bahoush, Golamreza [1 ]
Vafapour, Maryam [1 ]
机构
[1] Iran Univ Med Sci, Ali Asghar Children Hosp, Fac Med, Tehran, Iran
关键词
neuroblastoma; hematopoietic stem cell transplantation; veno-occlusive disease; Defibrotide; SYNDROME/VENO-OCCLUSIVE DISEASE; EUROPEAN-SOCIETY; BLOOD; CLASSIFICATION; DIAGNOSIS; CRITERIA; PHASE-3;
D O I
10.4081/ejtm.2020.9161
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Veno-occlusive disease (VOD) is one of the complications of hematopoietic stem cell transplantation that can also be caused by high-dose chemotherapy. This complication can lead to high mortality following bone marrow transplantation. It is more common after allogeneic stem cell transplantation, and is rare after autologous stem cell transplantation. While mild cases of VOD may reduce over a period of a few weeks, very severe cases can cause multi-organ damage, which has a high mortality. is therefore required with early diagnosis and treatment of this complication. In this paper, we present a sever VOD case after autologous stem cell transplantation, that was treated successfully with Defibrotide. The patient was a 14-month-old girl who has neuroblastoma with bone metastasis. VOD should be considered in the differential diagnosis of haematopoietic stem cell transplantation recipients who present with unexplained liver injuries, ascites and/or multi organ failure. Recipients of haematopoeitic stem cell transplantation who present with unexplained liver injuries, ascites and/or multi organ failure should have VOD considered in their differential diagnosis. If there is severe VOD diagnosed, then Defibrotide could be an option for treatment.
引用
收藏
页数:5
相关论文
共 50 条
  • [31] Case report:: defibrotide combined with N-acetylcysteine for the treatment of a patient with hepatic veno-occlusive disease after myelablative therapy with busulfan and melphalane and autologous stem cell transplantation
    Gerecke, C
    Hildebrandt, M
    Laske, K
    Dörffel, W
    Ludwig, WD
    Bargou, R
    BONE MARROW TRANSPLANTATION, 2005, 35 : S329 - S329
  • [32] Veno-Occlusive Disease in Hematopoietic Stem Cell Transplantation Recipients
    Sosa, Elisabeth C.
    CLINICAL JOURNAL OF ONCOLOGY NURSING, 2012, 16 (05) : 507 - 513
  • [33] Defibrotide for children and adults with hepatic veno-occlusive disease post hematopoietic cell transplantation
    Corbacioglu, Selim
    Richardson, Paul G.
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2017, 11 (10) : 885 - 898
  • [34] Safety and efficacy of defibrotide for the treatment of severe hepatic veno-occlusive disease
    Richardson, Paul G.
    Ho, Vincent T.
    Giralt, Sergio
    Arai, Sally
    Mineishi, Shin
    Cutler, Corey
    Antin, Joseph H.
    Stavitzski, Nicole
    Niederwieser, Dietger
    Holler, Ernst
    Carreras, Enric
    Soiffer, Robert
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2012, 3 (04) : 253 - 265
  • [35] Efficient prophylaxis with defibrotide for hepatic veno-occlusive disease (VOD) after allogeneic stem cell transplantation (SCT).
    Chalandon, Y
    Roosnek, E
    Helg, C
    Newton, A
    Wacker, P
    Chapuis, B
    BLOOD, 2002, 100 (11) : 111A - 111A
  • [36] Hepatic veno-occlusive disease after tandem autologous stem cell transplantation conditioned by melphalan
    Sana Intidhar Labidi
    Catherine Sebban
    Hervé Ghesquières
    Emmanuele Virelizier Nicolas
    Pierre Biron
    International Journal of Hematology, 2008, 88 : 291 - 293
  • [37] Hepatic veno-occlusive disease after tandem autologous stem cell transplantation conditioned by melphalan
    Labidi, Sana Intidhar
    Sebban, Catherine
    Ghesquieres, Herve
    Nicolas, Emmanuele Virelizier
    Biron, Pierre
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2008, 88 (03) : 291 - 293
  • [38] Cost-Effectiveness of Defibrotide in the Prophylaxis of Veno-Occlusive Disease after Pediatric Allogeneic Stem Cell Transplantation
    Pichler, Herbert
    Homer, Karolina
    Engstler, Gernot
    Poetschger, Ulrike
    Glogova, Evgenia
    Karlhuber, Susanne
    Martin, Manuel
    Eibler, Werner
    Witt, Volker
    Holter, Wolfgang
    Matthes-Martin, Susanne
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2017, 23 (07) : 1128 - 1133
  • [39] Defibrotide for Treatment of Hepatic Veno-Occlusive Disease Following Hematopoietic Stem Cell Transplantation: Results from the Japanese Therapeutic Use Protocol
    Kikuta, Atsushi
    Fukuda, Takahiro
    Ohashi, Kazuteru
    Taniguchi, Shuichi
    Asano-Mori, Yuki
    Horibe, Keizo
    Goto, Hiroaki
    Nakamae, Hirohisa
    Ogawa, Hiroyasu
    Tamaki, Hiroya
    Takahashi, Yoshiyuki
    Kimura, Toshimi
    Yoshimura, Kenichi
    Umemura, Kazuo
    Ogawa, Chitose
    BONE MARROW TRANSPLANTATION, 2018, 53 : 318 - 319
  • [40] Prophylactic defibrotide in allogeneic stem cell transplantation: minimal morbidity and zero mortality from veno-occlusive disease
    F Dignan
    D Gujral
    M Ethell
    S Evans
    J Treleaven
    G Morgan
    M Potter
    Bone Marrow Transplantation, 2007, 40 : 79 - 82